Cerus Corporation (CERS)’s Financial Results Comparing With Anavex Life Sciences Corp. (NASDAQ:AVXL)

Cerus Corporation (NASDAQ:CERS) and Anavex Life Sciences Corp. (NASDAQ:AVXL) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerus Corporation 60.62M 13.30 52.84M -0.42 0.00
Anavex Life Sciences Corp. N/A 0.00 20.73M -0.38 0.00

Table 1 demonstrates Cerus Corporation and Anavex Life Sciences Corp.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Cerus Corporation -87.17% -68.9% -38%
Anavex Life Sciences Corp. 0.00% -70.2% -61.8%

Risk and Volatility

Cerus Corporation’s 1.46 beta indicates that its volatility is 46.00% more volatile than that of Standard & Poor’s 500. Anavex Life Sciences Corp.’s 85.00% more volatile than Standard & Poor’s 500 volatility due to the company’s 1.85 beta.

Liquidity

Cerus Corporation’s Current Ratio and Quick Ratio are 3.5 and 3.2 respectively. The Current Ratio and Quick Ratio of its competitor Anavex Life Sciences Corp. are 8.3 and 8.3 respectively. Anavex Life Sciences Corp. therefore has a better chance of paying off short and long-term obligations compared to Cerus Corporation.

Insider and Institutional Ownership

Cerus Corporation and Anavex Life Sciences Corp. has shares owned by institutional investors as follows: 63.3% and 18.2%. Cerus Corporation’s share owned by insiders are 1.6%. Comparatively, Anavex Life Sciences Corp. has 5.17% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerus Corporation 4.95% -6.61% -22.72% -16.39% 50.96% 63.02%
Anavex Life Sciences Corp. -8.3% -17% -19.23% -48.53% -41.83% -34.78%

For the past year Cerus Corporation has 63.02% stronger performance while Anavex Life Sciences Corp. has -34.78% weaker performance.

Summary

On 5 of the 9 factors Cerus Corporation beats Anavex Life Sciences Corp.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.